The selectively increased risk of SCC formation in CsA-treated patients[@R1] suggested that that calcineurin signalling, central to keratinocyte growth/differentiation control [@R2]--[@R4], plays an intrinsic role in keratinocyte tumour suppression. Mice with keratinocyte-specific deletion of the calcineurin B1 gene (CnB1), essential for calcineurin activity [@R3], exhibited increased susceptibility to chemically-induced carcinogenesis, with decreased latency, higher incidence and size of tumours, and earlier malignant conversion ([Fig. 1a](#F1){ref-type="fig"}, [Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}).

To assess the relevance of these findings to human skin, primary human keratinocytes (HKCs) were infected with an oncogenic *H-ras^V12^*-transducing retrovirus, followed by skin-reconstitution grafting assays onto immune compromised (Scid) mice. In control mice, *H-ras^V12^*-expressing HKCs produced an acanthotic epithelium with normal pattern of differentiation. In CsA-treated mice, grafted cells gave rise to tumours with disordered proliferation and histopathological features of moderately to poorly differentiated SCC ([Fig. 1b](#F1){ref-type="fig"}; [Suppl. Fig. 2a](#SD1){ref-type="supplementary-material"}). Similar results were obtained by cell injection at the dermal-epidermal junction, i.e. a location approximating that of malignant skin tumour formation. *Ras*-expressing HKCs formed only differentiated epidermal cysts in control animals, while, in animals treated with CsA or the unrelated calcineurin inhibitor FK506, they produced highly cellular lesions with decreased differentiation ([Fig. 1c](#F1){ref-type="fig"}, [Suppl. Fig. 2b](#SD1){ref-type="supplementary-material"}). Similar lesions were produced by *H-ras^V12^*-expressing HKCs with siRNA-mediated knock-down of the CnB1 gene ([Fig. 1c](#F1){ref-type="fig"}, [Suppl. Fig. 2c](#SD1){ref-type="supplementary-material"}), and in mice treated with a calcineurin/NFAT inhibitory peptide (VIVIT)[@R5], versus control scrambled peptide (VEET) ([Suppl. Fig. 2d--f](#SD1){ref-type="supplementary-material"}).

Cutaneous SCCs are characterized by mutation and/or decreased expression of p53, but only 10--20% have *ras* mutations[@R6], raising the question of the relevance of the present findings for cancer cells without *ras* activation. Nucleotide sequencing showed that SCC12 and SCC13 cells, two independent lines from cutaneous SCC with poorly aggressive properties [@R7], have wild type *ras* genes and, as reported [@R8],[@R9], single p53 missense mutations. Up-regulation of endogenous p53 in these cells still induces "canonical" effectors like p21^WAF1/Cip1\ 10^, possibly through an indirect mechanism like the reported ability of mutant p53 to bind and titrate p63[@R11],[@R12], a negative regulator of p21 expression and senescence in keratinocytes[@R13],[@R14]. Injection of SCC12 and SCC13 cells at the dermal-epidermal junction resulted in differentiated cysts. By contrast, in mice treated with CsA or VIVIT, or as a consequence of p53 knockdown, SCC cells formed highly cellular and moderately differentiated infiltrating tumours ([Suppl. Figs.3,4a](#SD1){ref-type="supplementary-material"}).

Cancer cell senescence is a failsafe mechanism against tumour development[@R15] which can be associated with increased expression of terminal differentiation markers[@R16]. Staining for senescence-associated β-galactosidase activity (SA-β-Gal)[@R17] was positive in lesions formed by *ras*-expressing HKCs or SCC13 cells in control but not CsA-treated mice ([Fig. 1d](#F1){ref-type="fig"}, [Suppl. Fig. 5a](#SD1){ref-type="supplementary-material"}). This was paralleled by differences in Ki67 and K1 differentiation marker expression ([Suppl. Fig. 6](#SD1){ref-type="supplementary-material"}). Similarly decreased SA-β-Gal staining was found in tumours formed by *ras*-expressing HKCs with knockdown of CnB1 or, as predicted from the literature, of p53, a key mediator of oncogene-induced senescence[@R15] ([Fig. 1e](#F1){ref-type="fig"}, [Suppl. Fig. 5b](#SD1){ref-type="supplementary-material"}). Senescence was also suppressed in tumours formed by SCC13 cells with p53 knockdown ([Suppl. Fig. 4b,c](#SD1){ref-type="supplementary-material"}).

*Ras* induced senescence of cultured cells was also counteracted by CsA or VIVIT treatment and p53 knockdown ([Suppl. Fig. 7a--c](#SD1){ref-type="supplementary-material"}). Induction of terminal differentiation markers was similarly suppressed ([Suppl. Fig. 7d](#SD1){ref-type="supplementary-material"}). Paralleling these changes and consistent with previous reports[@R15], oncogenic *ras* expression caused increased p53 protein levels, without effects on transcription ([Suppl. Fig. 7e](#SD1){ref-type="supplementary-material"}). Importantly, calcineurin/NFAT inhibition counteracted the *ras* effects suppressing p53 expression not only at the protein but also mRNA level ([Suppl. Fig. 7e](#SD1){ref-type="supplementary-material"}).

In HKCs and SCC cells, p53 gene transcription is under negative control of the AP-1 complex, specifically c-Jun and c-Fos[@R10]. Real time RT-PCR and immunoblotting showed that c-Jun and c-Fos levels were unaffected by CsA or VIVIT treatment of HKCs. By contrast, expression of ATF3, a member of the "enlarged" AP-1 family previously connected with SCC progression[@R18], was sharply up-regulated ([Fig. 2a](#F2){ref-type="fig"}, [Suppl. Fig. 8a](#SD1){ref-type="supplementary-material"}). ATF3 expression also increased after Calcineurin B1 or NFATc1 knockdown ([Fig. 2b](#F2){ref-type="fig"}; [Suppl. Fig. 8b,c](#SD1){ref-type="supplementary-material"}), and in SCC13 cells treated with CsA or VIVIT ([Suppl. Fig. 8d](#SD1){ref-type="supplementary-material"}). Enhanced ATF3 expression in CsA- or VIVIT-treated keratinocytes was paralleled by increased binding of the ATF3 protein to specific oligonucleotide sequences of the p53 promoter containing intact, but not mutated, ATF3 binding sites ([Suppl. Fig. 8e](#SD1){ref-type="supplementary-material"}). Increased ATF3 expression in CsA-treated keratinocytes was suppressed by retrovirally expressed constitutively active NFATc1[@R19] ([Fig. 2c](#F2){ref-type="fig"}, [Suppl. Fig. 8f](#SD1){ref-type="supplementary-material"}). The kinetics of NFATc1 knockdown and ATF3 up-regulation were highly correlated ([Suppl. Fig. 8g](#SD1){ref-type="supplementary-material"}), and induction of ATF3 by CsA or VIVIT occurred to similar or greater extent when protein synthesis was inhibited ([Fig. 2d](#F2){ref-type="fig"}). Consistent with ATF3 being a direct target, chromatin immunoprecipitation assays showed binding of endogenous NFATc1 to two distinct regions of the ATF3 promoter harboring NFAT binding sites, such binding being abolished by NFATc1 knockdown or CsA treatment ([Fig. 2e](#F2){ref-type="fig"}, left panel). In intact human epidermis, we also detected NFATc1 binding to the ATF3 promoter comparable to a well established NFATc1 target, the calcipressin gene (RCNA1)[@R20] ([Fig. 2e](#F2){ref-type="fig"}, right panel).

CsA treatment caused ATF3 up-regulation and p53 down-modulation also in human skin explants and tumour xenografts ([Suppl. Fig. 8h,i](#SD1){ref-type="supplementary-material"}). Increased ATF3 and decreased p53 expression was also observed in SCCs from CsA-treated patients versus untreated patients, together with decreased senescence ([Fig. 2f](#F2){ref-type="fig"}, [Suppl. Fig. 9](#SD1){ref-type="supplementary-material"}). Increased ATF3 expression in SCCs from CsA-treated patients was further confirmed by tissue array/immunohistochemical analysis of a cohort of tumour biopsies ([Fig. 2g](#F2){ref-type="fig"}). Nucleotide sequence analysis of p53 in 5 SCCs from CsA-treated patients revealed missense mutations affecting the DNA binding domain and/or polymorphisms associated with cancer development (72 Pro/Arg substitution) similar to those in the general patient population ([www-p53.iarc.fr](www-p53.iarc.fr)).

Functionally, ectopic ATF3 expression, at levels comparable to those occurring in SCCs from CsA-treated patients ([Fig. 2f](#F2){ref-type="fig"}), blocked expression of p53 and senescence-associated genes ([Fig. 3a,b](#F3){ref-type="fig"}). Conversely, ATF3 knockdown induced these genes, counteracting the CsA and VIVIT effects ([Fig. 3c,d](#F3){ref-type="fig"}, [Suppl. Fig. 10](#SD1){ref-type="supplementary-material"}). *In vivo*, ectopic ATF3 promoted tumourigenicity of *H-ras^V12^*-expressing HKCs and SCC cells, produced aggressive tumours with reduced senescence as those caused by calcineurin/NFAT inhibitors ([Fig. 3e,f](#F3){ref-type="fig"}; [Suppl. Fig. 11a,b,e](#SD1){ref-type="supplementary-material"}). Conversely, ATF3 knockdown overcame the tumour promoting effects of these compounds and restored senescence ([Fig. 3g,h](#F3){ref-type="fig"}; [Suppl. Fig. 11c,d](#SD1){ref-type="supplementary-material"}).

Senescence serves to restrict tumourigenic potential of cells[@R15]. To test whether calcineurin inhibition exerts opposite effects, *H-ras^V12^*-expressing HKCs were sorted for elevated integrin α6 and low CD71 levels (α6^bri^ CD71^dim^ cells), enriching for cells with high self renewal potential[@R21]. In culture, response of α6^bri^ CD71^dim^ cells to VIVIT and CsA treatment, in term of ATF3 and p53 levels, was similar to that of total unsorted populations (data not shown). To assess their *in vivo* behaviour, *H-ras^V12^*-expressing α6^bri^ CD71^dim^ cells were injected in serial dilutions, together with constant amount of normal HKCs, into NOD/SCID interleukin-2 receptor gamma chain null (Il2rg(−/−)) mice[@R22]. Addition of matrigel allowed retention of injected cells in well identifiable "nodules". Histological analysis of nodules from control mice at 1 month after injection showed that *H-ras^V1^****^2^***-expressing HKCs injected in low number formed only a few keratinized cysts with limited cellularity. By contrast, in nodules recovered from CsA-treated mice there was a striking number of "proliferative centers", composed of keratinocytes with elevated Ki67 positivity ([Fig. 4a,b](#F4){ref-type="fig"}; [Suppl. Fig. 12](#SD1){ref-type="supplementary-material"}). When injected in higher number, *H-ras^V12^*-expressing HKCs formed highly keratinized and poorly proliferative cysts in control mice, while in CsA-treated animals they gave rise to overt tumours ([Fig. 4c](#F4){ref-type="fig"}). Similar results were obtained with sorted *H-ras^V12^*- and ATF3- expressing HKCs versus controls ([Fig. 4b,c](#F4){ref-type="fig"}).

Established cancer cell lines, including SCC cells, also contain distinct sub-populations with different growth/tumourigenic potential[@R23],[@R24]. SCC13 cells plus/minus increased ATF3 expression were sorted for elevated integrin α6 and low CD71 levels (cells) or for expression of CD133, a cell surface marker of putative cancer stem cell populations, including keratinocyte-derived[@R24]. Sorting resulted in \>20 fold enrichment of tumourigenic cells. As few as 500 sorted SCC13 cells overexpressing ATF3 produced detectable tumours, while larger numbers of control cells were required ([Fig. 4d](#F4){ref-type="fig"}; [Suppl. Fig. 13a](#SD1){ref-type="supplementary-material"}). Histologically, even the lowest number of ATF3-expressing cells produced highly cellular tumours with poor differentiation, while control cells formed differentiated cystic lesions ([Fig. 4d,e](#F4){ref-type="fig"}, [Suppl. Fig. 13a,b](#SD1){ref-type="supplementary-material"}).

In further testing, as little as 1000 freshly dissociated cells from tumours formed by *H-ras^V12^*-expressing HKCs in CsA-treated mice gave rise to secondary tumours, while substantially higher cell numbers were required in control mice ([Fig. 4f](#F4){ref-type="fig"}). Similar results were obtained with *H-ras^V12^*-expressing HKCs or SCC13 cells plus/minus increased ATF3 expression ([Fig. 4f,g](#F4){ref-type="fig"}). Histologically, secondary tumours formed in CsA-treated mice or by ATF3-expressing cells were highly cellular and poorly differentiated, while those under control conditions consisted, as the primary tumours, of differentiated cysts ([Fig. 4f,g](#F4){ref-type="fig"}, [Suppl. Fig. 14](#SD1){ref-type="supplementary-material"}).

Many regulatory pathways, including calcineurin/NFAT[@R2]--[@R4],[@R25], play both growth-promoting and -suppressing functions, depending on cell type and context. An impact on tumour growth has been recently attributed to calcineurin via indirect effects on angiogenesis[@R26],[@R27]. The intrinsic double negative genetic pathway that we have uncovered here is based on calcineurin/NFAT suppression of ATF3, a negative regulator of p53. The resulting impact on keratinocyte cancer cell senescence versus growth is of likely clinical significance for the many patients under treatment with calcineurin inhibitors as immunosuppressants[@R1], and may be of relevance for other cancer types where altered calcium signalling plays a role[@R28].

Methods summary {#S1}
===============

Multistep skin carcinogenesis assays were performed with mice with keratinocyte-specific deletion of the CnB1 gene (CnB1^loxP/loxP^xK5-CrePR1)[@R3] in parallel with Cre-negative controls (CnB1^loxP/loxP^). Keratinocyte grafting assays were performed as previously described[@R29]. Intradermal tumourigenicity assays were adapted from hair follicle reconstitution assays[@R30]. Detailed conditions for these assays as well as chromatin immunoprecipitation, immunoblotting, immunofluorescence, senescence β-galactosidase staining, biotinylated DNA pull down assays, and sorting can be found in the [Method section](#SD2){ref-type="supplementary-material"} and [supplementary figure](#SD1){ref-type="supplementary-material"} legends.
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![Calcineurin/NFAT inhibition promotes keratinocyte tumour formation\
**a**, Multistep skin carcinogenesis of mice with keratinocyte-specific CnB1 deletion (CnB1 −/−)[@R3] together with littermate controls (CnB1+/+). Numbers of total and large (\>4.5mm diameter) tumours were determined weekly. For histology see [Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}. **b,** Grafting of H-*ras*^V12^ expressing HKCs onto Scid mice plus/minus subsequent CsA treatment. Epidermal-dermal junction: black arrows. For higher magnification images and experimental conditions see [Suppl. Fig. 2a](#SD1){ref-type="supplementary-material"}. **c,** H-*ras*^V12^ expressing HKCs were injected at dermal-epidermal junction of Scid mice plus/minus subsequent CsA or FK506 treatment. Similar assays were performed with H-*ras*^V12^ expressing HKCs with siRNA-mediated CnB1 knockdown (siCnB1) versus control (siCtrl). Histological analysis was 10 days later, summarized on the right. For higher magnification images and experimental conditions: [Suppl. Fig. 2b,c](#SD1){ref-type="supplementary-material"}. **d** and **e,** Lesions formed by H-*ras*^V12^ expressing HKCs or SCC13 cells in mice plus/minus CsA-treatment (**d**) or plus/minus CnB1 and p53 knockdown (**e**) were analyzed by *in situ* chromogenic assay for senescence associated β-galactosidase activity[@R17]. For additional images, data quantification, experimental conditions see [suppl. Figs. 3--5](#SD1){ref-type="supplementary-material"}.](nihms185910f1){#F1}

![Calcineurin/NFAT signalling negatively controls ATF3 expression\
**a** and **b,** HKCs plus/minus CsA or VIVIT treatment (**a)** or CnB1 or NFATc1 knockdown (**b**) were analyzed in parallel with controls by immunoblotting. Similar results were obtained at mRNA level ([Suppl. Fig. 8a--c](#SD1){ref-type="supplementary-material"}). **c**, HKCs infected with retroviruses expressing constitutively active NFATc1 (+)[@R19] or GFP control (−) plus/minus subsequent CsA treatment were analyzed for ATF3 expression. Similar results were obtained by real time RT-PCR ([Suppl. Fig. 8f](#SD1){ref-type="supplementary-material"}). **d**, HKCs plus/minus CsA/VIVIT treatment and cycloheximide exposure were analyzed at various times (hours) for ATF3 expression by real time RT-PCR. Error bars represent mean ± s.d (n = 3 replicates). **e,** Extracts of HKCs plus/minus CsA treatment or NFACTc1 knockdown (left panel) or intact human epidermis (right panel) were processed for Chip with anti-NFATc1 antibodies or non-immune IgGs, followed by real time PCR of ATF3 promoter regions containing and lacking high-affinity NFATc1 binding sites (black and white boxes in the map above). Chip assays of the NFAT binding region of the calcipressin (RCNA1) gene[@R20], and a β-actin genomic region without NFAT binding sites were included. **f,** SCCs from 3 patients under CsA treatment and from untreated patients (Untr) from the general population were analyzed by immunoblotting for ATF3 expression, in parallel with HKCs infected with an ATF3 expressing retrovirus (ATF3) versus empty vector control. Similar differences in ATF3 mRNA expression were observed with an independent set of patients ([Suppl. Fig. 9a](#SD1){ref-type="supplementary-material"}). **g,** tissue arrays of cutaneous SCCs from patients under CsA treatment versus general untreated population (Untr) were analyzed for ATF3 expression by immunohistochemistry. Representative staining is shown along with quantification of ATF3 positive nuclei in each visual field of tumour tissues. Error bars represent mean ± s.d (n = 18, 16, 126 and 127 tumors per group, in the order).](nihms185910f2){#F2}

![ATF3 up-regulation enhances keratinocyte tumour formation and suppresses cancer cell senescence\
**a,** HKCs infected with ATF3 expressing (ATF3) and control retroviruses were analyzed by real time RT-PCR for indicated genes. Error bars represent mean ± s.d (n = 3 replicates). **b,** HKCs plus/minus infection with ATF3 and H-*ras*^V12^ expressing retroviruses were analyzed for p53 expression by immunoblotting. **c,** HKCs plus/minus ATF3 knockdown and CsA/VIVIT treatment were analyzed by real time RT-PCR for p53 and DcR2 expression. Additional results are shown in [Suppl. Fig. 10a](#SD1){ref-type="supplementary-material"}. **d,** HKCs plus/minus H-*ras*^V12^ expression, ATF3 knockdown and CsA treatment as indicated were analyzed for ATF3 and p53 expression by immunoblotting. For densitometric quantification and experimental conditions see [Suppl. Fig. 10b](#SD1){ref-type="supplementary-material"}. **e** and **f,** H-*ras*^V12^ expressing HKCs (**e**) or SCC13 cells (**f)** infected with ATF3 expressing and control retroviruses were injected at the dermal-epidermal junction of Scid mice. Shown are histological images of lesions recovered 6 weeks later. For quantification see [Suppl. Fig. 11a,b](#SD1){ref-type="supplementary-material"}. **g,** H-*ras*^V12^ expressing HKCs plus/minus ATF3 knockdown were injected at the dermal-epidermal junction of Scid mice, followed by CsA treatment. Mice were sacrificed 10 days later. For histological images see [Suppl. Fig. 11c](#SD1){ref-type="supplementary-material"}. **h** Lesions from the previous experiment were analyzed for SA-β-galactosidase activity. Low magnification images and quantification are shown in [Suppl. Fig. 11d](#SD1){ref-type="supplementary-material"}.](nihms185910f3){#F3}

![Calcineurin inhibition and increased ATF3 enhance cancer initiating cell populations\
**a--c,** *Ha-ras^V12^* expressing HKCs sorted for high α6 integrin and low CD71 expression (α6^bri^CD71^dim^ cells) were injected in the indicated numbers into NOD/SCID-Il2rg(−/−) mice[@R22], plus/minus subsequent CsA treatment for 4 weeks. Similar experiments were also performed with sorted H-*ras^V12^*expressing HKCs plus/minus ATF3 overexpression. **a**: histological images of nodules formed by 2,500 *Ha-ras^V12^*-HKCs in mice plus/minus CsA treatment. **b,** quantification of proliferative centers and, **c**, cysts or solid tumours formed by the indicated cell numbers. Error bars represent mean ± s.d (n = 4 nodules per condition). For low magnification images, quantification criteria and immunofluorescence analysis see [Suppl. Fig. 12a,b](#SD1){ref-type="supplementary-material"}. **d** and **e**, sorted α6^bri^CD71^dim^ populations of SCC13 cells plus/minus ATF3 overexpression were injected in the indicated numbers into Scid mice. Shown are quantification of the results and representative histological images. Experimental conditions were the same as with CD133 sorted cells ([Suppl. Fig. 13](#SD1){ref-type="supplementary-material"}). **f** and **g,** Cells dissociated from tumours formed by *Ha-ras^V12^*-HKCs in mice plus/minus CsA treatment, or with ATF3 overexpression (**f**) or from tumours formed SCC13 cells plus/minus ATF3 overexpression (**g)** were injected in decreasing numbers into secondary recipient mice (Scid), with tissue retrieval 4 weeks later. For representative images and experimental conditions see [Suppl. Fig. 14](#SD1){ref-type="supplementary-material"}.](nihms185910f4){#F4}
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